

Attention Pharmacies

The FDA has issued a Drug Safety Communication investigating the use of the pain medicine tramadol in children aged 17 years and younger because of the rare but serious risk of slowed or difficult breathing. After reviewing the current extensive usage of tramadol in Idaho Medicaid pediatric patients, the Drug Utilization Review (DUR) Board has recommended instituting prior authorization effective 4-17-17 for all pediatric patients with criteria to include a benefit vs. risk analysis for using tramadol in a pediatric patient as well as why alternative agents including non-pharmacological therapy, non-opioid pharmacological therapy, and other opioids cannot be used. Prescribers of tramadol to children in the last three months have already been sent a letter by the DUR Board informing them of this new prior authorization requirement.

If you have any questions please contact the Idaho Clinical Call Center at 208-364-1829.

Thank You,

MagellanRx
MANAGEMENT

